Emerging trophoblast cell-surface antigen 2-targeting antibody-drug conjugates in gynecological cancers
Frontiers in Oncology · 09.11.2026 · 16
DOI: 10.3389/fonc.2026.2005008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 09.11.2026. Verfasst von Erica Perri und 15 weiteren Autor:innen. Die Arbeit nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Trophoblast cell surface antigen 2 (TROP-2) is a transmembrane glycoprotein involved in intracellular signaling pathways that regulate cancer proliferation, invasion, and survival. TROP-2 is minimally expressed in normal tissues but widely overexpressed in epithelial malignancies, including breast, lung, pancreatic, bladder, and gynecologic cancers. Notably, high levels of TROP-2 RNA and protein expression have been reported in endometrial, ovarian, and cervical cancers, supporting its role in tumor progression and its potential value as a therapeutic target. Recent developments have identified TROP-2 as a promising target for antibody-drug conjugates (ADC)s, particularly in advanced or recurrent gynecologic malignancies where therapeutic resistance remains a major clinical challenge. Although immunotherapy, Poly (ADP-ribose) polymerase (PARP) inhibitors and chemotherapy have shown efficacy in subsets of patients, a significant unmet need persists, especially in those previously treated with platinum-based regimens and immune checkpoint inhibitors. Encouraging preclinical data and early-phase clinical trials have prompted the investigation of several anti-TROP-2 ADCs, including sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan. These agents leverage the selective expression of TROP-2 on tumor cells to deliver cytotoxic payloads, while also demonstrating a bystander effect that extends activity to antigen-negative cells. Their clinical application is currently being explored in gynecologic settings. In this review, we provide an overview of TROP-2’s biological role and its relevance as a prognostic and predictive biomarker in gynecologic cancers. We further summarize the available clinical data on TROP-2-targeting ADCs and discuss future perspectives for integrating these agents into therapeutic strategies aimed at improving outcomes in ovarian, endometrial, and cervical cancers.
Zitieren
APA
Perri, E., Lamia, M. R., Pisano, C., Cecere, S. C., Napoli, M. D., Lobianco, L., Rossetti, S., Tambaro, R., Ventriglia, J., D’Alessio, C., Coppola, E., Scarpa, E., Pacifico, G., Terrano, V., Pignata, S., & Passarelli, A. (2026). Emerging trophoblast cell-surface antigen 2-targeting antibody-drug conjugates in gynecological cancers. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.2005008
Vancouver
Perri E, Lamia MR, Pisano C, Cecere SC, Napoli MD, Lobianco L, et al. Emerging trophoblast cell-surface antigen 2-targeting antibody-drug conjugates in gynecological cancers. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.2005008
BibTeX
@article{Perri2026,
author = {Perri, Erica and Lamia, Maria Rosaria and Pisano, Carmela and Cecere, Sabrina Chiara and Napoli, Marilena Di and Lobianco, Lorenzo and Rossetti, Sabrina and Tambaro, Rosa and Ventriglia, Jole and D’Alessio, Chiara and Coppola, Elisabetta and Scarpa, Emilia and Pacifico, Giovanni and Terrano, Vincenzo and Pignata, Sandro and Passarelli, Anna},
title = {Emerging trophoblast cell-surface antigen 2-targeting antibody-drug conjugates in gynecological cancers},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.2005008}
}
EUVIMED